Please ensure Javascript is enabled for purposes of website accessibility

This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher

By Alex Carchidi - Jun 10, 2021 at 7:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With updates from clinical trials expected as soon as this month, anything is possible.

When a biotech stock heads to the moon after releasing data on one of its drug programs, sometimes the party is just getting started.

And that might be exactly the case for Annovis Bio (ANVS 2.88%), a biotech that's trying to tackle Alzheimer's disease and other neurodegenerative disorders. It's no secret that Alzheimer's is among the most challenging conditions to make drugs for. So, when the company let the world know that its lead program was showing convincing signs of being effective, the market rejoiced. Many others have failed where Annovis now intends to succeed -- but are things different this time, and can new investors benefit?

A doctor shows a brain scan to an older couple looking on intently.

Image source: Getty Images.

Annovis could grow even more

The first thing to understand about Annovis is that it's taking a new scientific approach. The company's lead Alzheimer's project, ANVS401, is notable because it targets three different neurotoxic proteins in the brain rather than just one. All of these proteins are associated with Alzheimer's, and two of them are associated with Parkinson's. While it's too early to say whether this strategy is effective, previous efforts by other developers have shown it isn't enough to target just one of the three neurotoxic proteins. Hitting three birds with one stone might bring different results.

When the company reported in late May that its small phase 2 clinical trial of ANVS401 had preliminarily shown that the treatment could improve the cognition of patients with Alzheimer's, the stock jumped from around $26 to nearly $91. The same study also showed that ANVS401 was helpful for improving the motor coordination of patients with Parkinson's disease. In a nutshell, the preliminary results are just as positive as the market's bombastic reaction. On one measure of cognitive functioning, patients treated with ANVS401 experienced an improvement of 30% relative to their baseline.

^SPX Chart

^SPX data by YCharts

Annovis has also secured an orphan drug designation for ANVS401 from the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease in people living with Down Syndrome. That's quite favorable, because the designation means that it can keep its intellectual property (IP) protections for a longer period while also getting tax credits worth up to 50% of research and development (R&D) costs. But the project is still in phase 1, so it's a bit behind the lead program. 

It's still a risky investment

For all the company's merits, it's important for potential investors to understand that Annovis doesn't have any revenue right now. There's no dressing up that it's a pre-product biotech stock. And despite the promising phase 2 data, Annovis has a long way to go before ANVS401 could start to make money.

To address this, on May 27 it closed a public offering worth $50 million, which is more than enough to cover its 2020 operating expenses of $5.48 million for quite some time. But, there's still a chance that the company will need more money before it has a chance to commercialize its drugs, especially if it hits any setbacks in the clinic. That means it might need to issue more stock. So, people who buy the stock right now risk dilution of their equity down the line. 

Plus, the company faces the standard roster of drug development risks during the clinical trials process. For central nervous system drug programs like Alzheimer's disease, only 15% of projects make it through the clinical trials process to reach commercialization. If its programs don't show substantial benefits to patients, shareholders might see the stock plummet when the news comes out. 

On the other hand, if Annovis can close the loop on ANVS401 by showing conclusively that it is beneficial for both Alzheimer's and Parkinson's, it'll be the first company ever to do so. The upside to shareholders would be absolutely tremendous. Before it has a chance to reach that distant goal, however, investors can look forward to more intermediate data readouts. On June 8, Annovis reported that a preclinical study had shown that ANVS401 stopped certain types of neurons from dying when exposed to the harmful bacteria porphyromonas gingivalis. That's a promising development, but it still needs to be proven with real patients.

The entire ANVS401 trial concludes in August, but as soon as June or July there could be a readout that elaborates on the drug's potential efficacy, so be sure to stay tuned.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Annovis Bio, Inc. Stock Quote
Annovis Bio, Inc.
ANVS
$12.49 (2.88%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.